CIK 0001232524 · Large accelerated filer
Jazz Pharmaceuticals plc
Sign in to watch- Ticker
- JAZZ
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Ireland
- Entity type
- operating
- EIN
- 981032470
- Phone
- 353-1-634-7800
- Business address
- FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, Ireland, D04 E5W7
- Former names
- JAZZ PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,420,682
- in 10 filings, $24.9M under 10b5-1 plans
Net −$41,420,682. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- COZADD BRUCE C −$20.4M Director sold 20% of stake
- Iannone Robert −$19.2M EVP, Global Head of R&D & CMO sold 54% of stake
- GALA RENEE D −$1.2M President & CEO sold 3% of stake
- Carr Patricia −$327K SVP, Chief Accounting Officer sold 18% of stake
- Patil Neena M −$289K EVP & Chief Legal Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-31 | LOVE TED W Director | Shares withheld for taxes | −6 | $244.06 | $1K | 3,126 |
| 2026-08-31 | LOVE TED W Director | Shares withheld for taxes | −737 | $241.39 | $178K | 2,389 |
| 2026-08-31 | RIEDEL NORBERT G Director | Shares withheld for taxes | −14 | $244.64 | $3K | 8,615 |
| 2026-08-31 | RIEDEL NORBERT G Director | Shares withheld for taxes | −1,692 | $241.39 | $408K | 6,923 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 | +26,116 | $113.10 | $3.0M | 111,223 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 | +884 | $113.10 | $100K | 112,107 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 | +27,584 | $137.12 | $3.8M | 139,691 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 | +2,916 | $137.12 | $400K | 142,607 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 | −18,187 | $247.86 | $4.5M | 124,420 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 | −11,423 | $248.67 | $2.8M | 112,997 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 | −18,113 | $250.02 | $4.5M | 94,884 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 | −19,639 | $250.60 | $4.9M | 75,245 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 | −9,259 | $251.95 | $2.3M | 65,986 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 | −300 | $252.76 | $76K | 65,686 |
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise · Incentive Stock Option (right to buy) 10b5-1 | −884 | 0 | ||
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise · Incentive Stock Option (right to buy) 10b5-1 | −2,916 | 0 | ||
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −26,116 | 0 | ||
| 2026-08-27 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −27,584 | 0 | ||
| 2026-08-05 | Kennedy Patrick Director | Grant or award | +1,605 | 8,307 | ||
| 2026-08-05 | Pearce Samantha EVP, Chief Commercial Officer | Shares withheld for taxes | −780 | $261.62 | $204K | 47,131 |
Page 3 of 19 · 365 trades